What Is a Washout Period and Why Is It Important?

A washout period is a planned gap between treatments during which a drug, supplement, or other intervention is allowed to clear the body before a new treatment begins or a study measurement is taken. It exists to prevent the lingering effects of one treatment from contaminating the results of whatever comes next. In clinical trials, the washout period is one of the most quietly important design choices researchers make, and when it goes wrong, the consequences range from misleading study results to real patient harm.

The Carryover Problem

The simplest way to understand why washout periods exist is to think about a study where the same person tests two different treatments, one after the other. This kind of study, called a crossover trial, is powerful because each participant serves as their own comparison, eliminating a lot of individual variation. But if the first treatment is still active in the body when the second treatment starts, the results become tangled. The leftover biological effect of treatment A bleeds into the measurement window for treatment B. Researchers call this a carryover effect, and it can make an ineffective treatment look helpful or a helpful treatment look ineffective.

One analysis of crossover trials in emergency medicine stressed that researchers should explicitly examine their assumptions about carryover effects and demonstrate that the washout period between treatment phases was adequate before drawing conclusions from their data.

1PubMed. Analysis of two-treatment, two-period crossover trials in emergency medicine

Statistical methods have been developed specifically to detect and measure carryover effects. Mixed-effects models, for instance, can estimate whether a treatment’s influence persists into the next phase of a study, even when the data are noisy or incomplete.

2Contemporary Clinical Trials Communications. Statistical methods for testing carryover effects: A mixed effects model approach

But statistical correction is a safety net, not a substitute for designing the washout period correctly in the first place. If the gap between treatments is fundamentally too short, no amount of modeling can fully untangle the overlap.

How Researchers Decide the Length

There is no universal washout duration. The length depends almost entirely on the drug or substance being studied and how long it takes to leave the body. The standard rule of thumb is to wait for at least five half-lives. A drug’s half-life is the time it takes for the concentration in the blood to drop by half. After five half-lives, roughly 97% of the drug has been eliminated. For a medication with a 6-hour half-life, that means a washout of about 30 hours. For a medication with a half-life measured in days, the washout stretches to weeks.

In practice, the five-half-life rule is only the starting point. Patient-specific factors like age, kidney function, and liver health can dramatically slow how quickly a drug clears. A guide on managing antiarrhythmic drugs before cardiac procedures details how washout times need to be adjusted upward for patients with impaired kidney or liver function, because the same drug can linger far longer in those individuals.

3PubMed. Antiarrhythmics Management During Electrophysiology Procedures: A Stepwise Approach

A review of cancer drug trials approved by the FDA found that the most common washout period fell between 14 and 28 days, with about half of the studies landing in that range. Some protocols specified no washout at all, while the longest was three months. The variation did not neatly track the mechanism of each drug, suggesting that many washout periods were chosen more by convention than by pharmacological reasoning.

4PubMed Central. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group

That same review noted that rationale for specific washout durations was rarely provided in the trial protocols, which is a persistent problem in the field. When trialists choose a washout period by borrowing what a previous study did rather than calculating what the pharmacology requires, the gap can end up too short or unnecessarily long.

Washout Periods in Everyday Medicine

Washout periods are not just a research tool. They show up in routine clinical care whenever a patient needs to switch from one medication to another, especially when the two drugs could interact dangerously if their effects overlap. Switching antidepressants is one of the most common situations where this matters.

A conservative approach to changing antidepressants involves gradually tapering the first medication, then waiting through a washout period before starting the new one. The reason is that mixing certain antidepressants, particularly those that boost serotonin through different pathways, can trigger serotonin syndrome, a potentially life-threatening condition involving agitation, rapid heart rate, and dangerously elevated body temperature.

5PubMed Central. Switching and stopping antidepressants

The washout duration in this context depends on the specific drug being stopped. Most SSRIs need a week or two, but fluoxetine, which has an unusually long half-life, can require a washout of five weeks or more. For patients, this gap without medication can feel difficult, which is why clinicians sometimes use a cross-taper strategy, carefully overlapping the two drugs at low doses rather than inserting a full washout. That approach carries its own risks and requires close monitoring.

The tension between safety and patient comfort is real. A washout period that is pharmacologically ideal might leave someone with untreated depression or anxiety for weeks, which is its own form of harm. Clinicians have to weigh the risk of drug interaction against the risk of untreated illness, and there is no formula that resolves that tradeoff automatically.

When Days or Weeks Are Not Enough

Some substances take far longer to leave the body than most people would guess, and this is where washout periods get genuinely tricky. The monoclonal antibody trastuzumab, used in breast cancer treatment, has a recommended serum washout period of seven months.

6PubMed Central. Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors

Large biologic molecules behave very differently from small-molecule pills. They are cleared slowly, they can accumulate in tissues, and their biological effects can persist well beyond the point where blood levels have dropped. For a researcher designing a trial that follows a trastuzumab-containing regimen, failing to account for that seven-month tail would mean measuring outcomes while the previous drug is still doing something in the body.

The challenge is not limited to cancer drugs. In sports nutrition research, beta-alanine supplementation is commonly studied for its ability to increase carnosine levels in muscle tissue. But a study measuring carnosine loading and washout found that muscle carnosine levels remained elevated for weeks after supplementation stopped. On average, only about one-third of the supplementation-induced increase had disappeared after three weeks. Full return to baseline took about nine weeks in the group as a whole, and as long as 15 weeks in high responders.

7PubMed. Carnosine loading and washout in human skeletal muscles

The researchers noted that crossover designs in supplementation studies for muscle metabolites may sometimes require months rather than weeks, a timeline many study protocols fail to account for. If a supplement study uses a two-week washout between phases, and the substance being studied takes nine weeks to clear from muscle tissue, the crossover design is fundamentally compromised even though the protocol looks tidy on paper.

The Observational Study Problem

Washout periods also appear in a completely different research context: observational studies that use health records to track what happens when people start a medication. In these studies, researchers want to identify “new users” of a drug, people who are starting it for the first time, because studying only new users avoids a bias that comes from including people who have already been on the medication and survived or tolerated it well. To find new users, researchers look backward through a patient’s records for a “washout window,” a period of time during which the patient had no prescriptions for the drug. If the window is clean, the patient is counted as a new user.

The problem is that these washout windows are often far too short. A study examining three common drug classes found that when researchers used a 12-month washout period, about a quarter of patients labeled as new users of diabetes medications had actually used the drug at some point during a longer lookback window. For cholesterol-lowering drugs and antidepressants, the misclassification rate was roughly a third. Shortening the washout to six months pushed the misclassification rate to about half, and a three-month washout resulted in two-thirds to three-quarters of supposedly new users being incorrectly classified.

8PubMed Central. Revisiting the washout period in the incident user study design: why 6–12 months may not be sufficient

This matters because studies that accidentally include experienced users tend to overestimate how safe and effective a drug is. People who had bad reactions or stopped the drug due to side effects have already dropped out of the pool, leaving a group that is biased toward good outcomes. The commonly used washout of 6 to 12 months, which many observational researchers treat as standard, appears to be genuinely insufficient for several widely prescribed medication classes. Longer lookback periods, when the data allow them, produce more reliable results.

Drug Interactions and Herbal Supplements

One area where washout periods receive less attention than they should is in research on herbal supplements and their potential to interact with prescription drugs. Many popular supplements affect the same liver enzymes that metabolize prescription medications, and studying those interactions cleanly requires careful washout design.

A study evaluating six common botanical supplements, including St. John’s wort, kava kava, and milk thistle, used a 30-day washout period between each supplementation phase when testing their effects on drug-metabolizing enzymes in healthy volunteers.

9PubMed Central. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John’s wort, and Echinacea

That 30-day gap is longer than many pharmaceutical crossover studies use, and for good reason: some herbal products alter enzyme activity in ways that take weeks to reverse. St. John’s wort, for instance, is a potent inducer of CYP3A4, the same enzyme pathway that nearly half of cancer clinical trials exclude interacting agents for.

4PubMed Central. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group

For patients taking prescription medications alongside herbal products, the interaction risk can persist well after the supplement bottle is put away, which is something that rarely comes up in casual conversations about “natural” remedies.

When Trials Skip the Washout

Not every study uses a washout period, and sometimes the decision to skip one is deliberate and defensible. Digital health interventions, for example, pose a genuine puzzle. If you are testing a behavioral app that teaches migraine-prevention techniques, you cannot “wash out” learned skills the way you can wait for a drug to clear the bloodstream. Two randomized trials of a digital therapeutic for episodic migraine prevention did not include washout periods, and participants continued their existing migraine medications throughout. The researchers acknowledged that this meant baseline measurements reflected participants’ migraine frequency while still benefiting from ongoing treatments, rather than a drug-free starting point.

10npj Digital Medicine. Integrated analysis of two randomized controlled trials of a digital therapeutic for episodic migraine prevention

The broader question of whether digital health trials should incorporate washout periods at all has been raised as a methodological challenge requiring international discussion.

11The Lancet Digital Health. International harmonisation of best evidentiary practices for digital health applications: an expert view

The concept was designed for pharmacological interventions with measurable biological clearance. When the intervention is educational, psychological, or behavioral, the notion of “clearing” the treatment from the body does not translate cleanly. This does not mean washout is irrelevant in digital health, but it does mean the field is still working out what a washout equivalent would look like.

Diet studies face a similar challenge, though they can partially solve it. A trial comparing different diets used a three-week washout between diet periods, during which participants ate their normal food, and confirmed through metabolic measurements that participants had returned to their baseline status before starting the next phase.

12Cell. A microbiome-restoration diet reduces-pathogens and chronic-disease risk-markers

That kind of verification, actually measuring whether the washout worked rather than just assuming it did, is considered good practice but is still the exception rather than the rule across most research fields.

Withdrawal Confounding in Relapse Prevention Studies

There is a less obvious way washout periods can distort research, and it involves studies designed to test whether staying on a drug prevents relapse. These trials typically take patients who are doing well on a medication, randomly assign some of them to switch to placebo, and then watch who relapses first. The washout here is the transition from active drug to placebo, and how that transition is managed turns out to matter enormously.

When the switch is abrupt, patients assigned to placebo may experience withdrawal symptoms that mimic the return of the underlying illness. A patient yanked off an antidepressant might develop insomnia, anxiety, and low mood within days, and researchers might score that as a depressive relapse when it is actually a drug withdrawal reaction. This problem, known as withdrawal confounding, has been flagged as a significant issue in psychopharmacology research, where abrupt or rapid discontinuations are common and investigators often pay little attention to the distinction between withdrawal and genuine relapse.

The proposed solutions include slower medication tapers before the placebo phase begins and active placebos that mimic some of the drug’s side effects, both of which amount to better-designed washout transitions. Without them, relapse prevention trials may systematically overstate how much patients need to stay on their medication, because the comparison is not really “drug versus no drug” but “drug versus the discomfort of suddenly losing the drug.”

Bioequivalence Testing and Generic Drugs

One of the most consequential uses of washout periods happens in the studies that determine whether a generic drug works the same as the brand-name version. These bioequivalence studies are almost always crossover designs: a volunteer takes the brand-name drug, blood samples are drawn over time to measure absorption, and then after a washout period, the same volunteer takes the generic version for the same measurements. The FDA requires this kind of evidence before approving a generic product.

13PubMed Central. Bioavailability and Bioequivalence in Drug Development

If the washout between the two phases is too short, residual drug from the first phase inflates the blood levels measured during the second phase, making the two products look more similar than they actually are, or less similar, depending on which was given first. Given that billions of generic prescriptions are dispensed each year, the integrity of these washout periods has real downstream consequences for public health. The standard approach is a washout of at least five half-lives, but for drugs with long half-lives or active metabolites, the gap may need to be substantially longer, and individual variation in metabolism means that a washout sufficient for most volunteers might still be inadequate for a few.

Practical Trial Design With Washout Periods

A well-designed trial typically sandwiches the washout period between other structured phases. A common pattern is a run-in period, then active treatment, then a washout, then a second treatment. A trial of quinine for muscle cramps, for example, used a two-week run-in with no treatment, followed by two weeks of either quinine or placebo, and then a two-week washout period without treatment.

14International Journal of Clinical Practice. EFFECTIVENESS OF QUININE IN TREATING MUSCLE CRAMPS: A DOUBLE‐BLIND, PLACEBO‐CONTROLLED, PARALLEL‐GROUP, MULTICENTRE TRIAL

The run-in period establishes a baseline and sometimes weeds out non-compliant participants. The washout period separates treatment phases. Together, they create the conditions under which the treatment comparison can be trusted.

But even in well-designed protocols, assumptions about washout adequacy are often left unexamined. A washout period gets written into the protocol, the study proceeds, and no one goes back to verify that the gap was actually sufficient. The carnosine study’s finding that washout can take months rather than weeks for certain tissue-level effects is a cautionary example. Researchers measuring blood levels of a drug might confirm clearance within days, but effects embedded in tissues, enzymes, or metabolic pathways can persist far longer than what shows up on a standard blood test.

For readers encountering washout periods in the context of their own care, whether switching medications, joining a clinical trial, or stopping a supplement, the key takeaway is that the duration matters and is not always chosen carefully. Asking your doctor why a specific washout length was recommended, and whether your individual factors like age or organ function were considered, is a reasonable and important question.